News
AMPE
0.9200
+12.20%
0.1000
Ampio Pharmaceuticals Q4 EPS $(2.48) Up From $(3.60) YoY
Benzinga · 21h ago
AMPE Stock Earnings: Ampio Pharmaceuticals Reported Results for Q4 2023
Ampio Pharmaceuticals reported earnings per share of -$2.48 for the first quarter. The company did not report any revenue for the quarter. Ampo Pharmaceuticals is not listed as a company in the S&P 500 index of large companies on Tuesday.
Investorplace · 22h ago
GOEV, NBSE and FLGC among pre-market losers
GOEV, NBSE and FLGC among pre-market losers. NeuBase Therapeutics (NBSE) -58%. AppTech Payments Corp (APCX) announces proposed underwritten public offering. Bluebird bio (BLUE) reports Q4 results.
Seeking Alpha · 2d ago
Ampio Shares Fall 22% as Co. Plans to Voluntarily Delist From NYSE American
Ampio Pharmaceuticals plans to voluntarily delist shares from the NYSE American Exchange. The company's stock hit a 52-week low of $1.50 on March 7. Ampio says it plans to suspend its reporting obligations under the Securities and Exchange Act of 1934. The delisting is expected to become effective April 14.
Dow Jones · 3d ago
Ampio Reports Voluntary Delisting And SEC Deregistration
Benzinga · 3d ago
Ampio Pharmaceuticals announces voluntary delisting and SEC deregistration
Ampio Pharmaceuticals announces voluntary delisting and SEC deregistration. Shares of AMPE sunk 38.7% in extended trading. The company expects the delisting to become effective on April 14, 2024. AMPE's board determined to voluntarily delist its common stock from the NYSE American and deregister its stock.
Seeking Alpha · 3d ago
Ampio Announces Voluntary Delisting and SEC Deregistration
Ampio Pharmaceuticals, Inc. Will voluntarily delist its common stock from the NYSE American and deregister its stock in April 2024. The Company has previously focused on the development of a potential treatment for osteoarthritis. The pain reduction benefit was not observed in the company's OA-201 program. The company intends to suspend its reporting obligations under the Exchange Act.
PR Newswire · 3d ago
Weekly Report: what happened at AMPE last week (0318-0322)?
Weekly Report · 3d ago
Earnings week ahead: Walgreens Boots Alliance, Carnival, GameStop and more
Several key companies are set to release their earnings reports for the week of March 25 to 29. Walgreens Boots Alliance, Carnival, GameStop and more are among the companies scheduled to report next week. The week is shortened by a market holiday on Friday and will be shortened to one day.
Seeking Alpha · 4d ago
Weekly Report: what happened at AMPE last week (0311-0315)?
Weekly Report · 03/18 10:44
Weekly Report: what happened at AMPE last week (0304-0308)?
Weekly Report · 03/11 10:42
Weekly Report: what happened at AMPE last week (0226-0301)?
Weekly Report · 03/04 10:44
12 Health Care Stocks Moving In Thursday's Intraday Session
Societal CDMO (NASDAQ:SCTL) stock rose 132.6% to $1.07 during Thursday's regular session. The company's, Q4 earnings came out yesterday. Enveric Biosciences shares increased by 132.25% and Envoy Medical stock rose 47.29% in the same session.
Benzinga · 02/29 17:32
Ampio Pharmaceuticals, Ironwood, Incannex among healthcare movers
Healthcare On the Move: Avidity Biosciences, Codexis among healthcare movers. S&P 500 Health Care Sector -0.14% to 1696.29. Pharmaceuticals, Biotechnology & Life Science contributes 58% to index. Ampio Pharmaceuticals,. Ironwood, Incannex among healthcare mover.
Seeking Alpha · 02/29 15:00
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Enveric Biosciences stock rose 162.3% to $2.18 during Thursday's pre-market session. The company's market cap stands at $5.9 billion. Enveric is one of a number of companies gaining in the pre- market session.
Benzinga · 02/29 13:07
12 Health Care Stocks Moving In Wednesday's After-Market Session
IGC Pharma shares moved upwards by 14.6% to $0.4 during Wednesday's after-market session. Establishment Labs Hldgs (NASDAQ:ESTA) shares rose 14.43% during the session. The company's, Q4 earnings came out today. Butterfly Network (NYSE:BFLY) shares decreased by 16.9% in the same session.
Benzinga · 02/28 21:31
Ampio Pharmaceuticals Ends Equity Distribution and Alters Strategy
TipRanks · 02/28 21:02
Ampio Pharmaceuticals Files FormRW To Terminate That Certain At The Marketing Offering Agreement, Dated September 18, 2023
Ampio Pharmaceuticals, Inc. Provided a notice to terminate that certain At The Marketing Offering Agreement. The termination of the ATM Agreement will be effective March 6, 2024. The Company filed a post-effective amendment to its Registration Statement on February 28, 2024 to remove shares of the Company's common stock.
Benzinga · 02/28 20:51
*Ampio Pharmaceuticals Withdraws Filing for Offering of Stock and Warrants
Dow Jones · 02/28 20:48
Weekly Report: what happened at AMPE last week (0219-0223)?
Weekly Report · 02/26 10:54
More
Webull provides a variety of real-time AMPE stock news. You can receive the latest news about Ampio Pharma through multiple platforms. This information may help you make smarter investment decisions.
About AMPE
Ampio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the preclinical development of AR-300, and is conducting studies to evaluate the efficacy of AR-300 in osteoarthritis-related pain. The Company is primarily targeting the clinical development of AR-300 for the treatment of osteoarthritis of the knee (OAK). AR-300 is a small-molecule formulation that has demonstrated anti-inflammatory properties in vitro and protection of cartilage in preclinical rat meniscal tear studies.